For the year ending 2025-12-31, PVLA had -$25,620K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -41,715 |
| Non-cash interest expense - royalty agreement | 5,818 |
| Non-cash interest expense - convertible notes | 0 |
| Change in fair value of derivative liabilities - royalty agreement | 394 |
| Change in fair value of derivative liabilities - contingent value right liability | 218 |
| Change in fair value of convertible notes payable | 0 |
| Stock-based compensation | 6,401 |
| Non-cash lease operating expense | 62 |
| Costs to issue convertible notes | 0 |
| Accounts receivable | -387 |
| German research and development tax credit receivable | -2,105 |
| Prepaid expenses and other current assets | -1,364 |
| Account payable | 1,260 |
| Accrued expenses and other current liabilities | -1,300 |
| Net cash used in operating activities | -25,006 |
| Cash acquired from reverse merger transaction | 0 |
| Payment of transaction costs in connection with reverse merger | 1,269 |
| Proceeds from pipe financing | 0 |
| Payments of transaction costs associated with pipe financing | 0 |
| Proceeds from issuance of convertible notes | 0 |
| Payment of transaction costs to issue convertible notes | 0 |
| Proceeds from exercise of stock options | 763 |
| Deferred equity issuance costs | 154 |
| Net cash (used in) provided by financing activities | -660 |
| Effect of exchange rate change on cash and cash equivalents | 46 |
| Net (decrease) increase in cash and cash equivalents | -25,620 |
| Cash and cash equivalents at beginning of period | 83,602 |
| Cash and cash equivalents at end of period | 57,982 |
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)